Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04465370 · ClinicalTrials.gov registry record
Pediatric Cardiac Output Monitoring Observational Study
A clinical trial, sponsored by Edwards Lifesciences.
- Completed
- Registry status
- 89
- Enrollment target
NCT04465370: Completed study, sponsored by Edwards Lifesciences.
NCT04465370 is a clinical trial that has completed, run by Edwards Lifesciences. The registered enrollment target is 89 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04465370 has completed, sponsored by Edwards Lifesciences.
- COMPLETED
- Registry status
- 89 participants
- Enrollment target
Study Summary
To assess Cardiac Output Monitoring in pediatric subjects by comparing FloTrac and ClearSight system to intermittent thermodilution Swan-Ganz, in order to expand the indications of FloTrac, ClearSight and Swan-Ganz thermodilution pulmonary artery catheter to the pediatric population 12 to 18 years of age.
Primary Outcome
Bias of FloTrac Arterial Pressure Cardiac Output (APCO) against Swan Ganz Invasive Cardiac Output (ICO) was calculated via Bland-Altman analysis
Interventions
- DEVICE Hemosphere Advanced Monitoring System, ClearSight 1.5, Swan-Ganz Catheter, Flotrac, Foresight
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 89 participants |
| Start Date | 2020-09-02 |
| Est. Completion | 2023-01-05 |
What the finished NCT04465370 record still lists
NCT04465370 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 89 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Hemosphere Advanced Monitoring System, ClearSight 1.5, Swan-Ganz Catheter, Flotrac, Foresight is the first listed.
NCT04465370 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04465370 about?
NCT04465370 is a clinical study titled "Pediatric Cardiac Output Monitoring Observational Study". To assess Cardiac Output Monitoring in pediatric subjects by comparing FloTrac and ClearSight system to intermittent thermodilution Swan-Ganz, in order to expand the indications of FloTrac, ClearSight and Swan-Ganz thermodilution pulmonary artery catheter to the pediatric population 12 to 18 years o...
What is the current status of trial NCT04465370?
This trial is currently completed. The enrollment target is 89 participants. The study started on 2020-09-02. Estimated completion is 2023-01-05.
What interventions are being tested in trial NCT04465370?
The interventions under investigation include: Hemosphere Advanced Monitoring System, ClearSight 1.5, Swan-Ganz Catheter, Flotrac, Foresight (DEVICE).
Who is sponsoring clinical trial NCT04465370?
This trial is sponsored by Edwards Lifesciences, which has 57 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03682289 · 89 participants · Phase 2
Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors
- NCT04787939 · 89 participants · NA
Early Feeding After Oral Cavity Reconstruction
- NCT05480449 · 89 participants · Phase 1
Autologous HuCART19 T Cells Manufactured Using the CliniMACS Prodigy Platform for Pediatric B-ALL (huCART19 Prodigy)
- NCT05604131 · 89 participants · Phase 2
Cardiac MRI-guided Deferiprone Therapy for Acute Myocardial Infarction Patients
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI